Head-To-Head Comparison: BioNTech (NASDAQ:BNTX) versus Inhibrx Biosciences (NASDAQ:INBX)

Inhibrx Biosciences (NASDAQ:INBX) and BioNTech (NASDAQ:BNTX) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, earnings, dividends, analyst recommendations and institutional ownership.

Analyst Ratings

This is a breakdown of current recommendations for Inhibrx Biosciences and BioNTech, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibrx Biosciences	1	2	2	1	2.50
BioNTech	1	4	13	1	2.74

Inhibrx Biosciences presently has a consensus target price of $197.50, indicating a potential upside of 62.99%. BioNTech has a consensus target price of $127.44, indicating a potential upside of 22.82%. Given Inhibrx Biosciences’ higher probable upside, analysts clearly believe Inhibrx Biosciences is more favorable than BioNTech.

Risk & Volatility

Inhibrx Biosciences has a beta of 3.66, suggesting that its stock price is 266% more volatile than the S&P 500. Comparatively, BioNTech has a beta of 1.29, suggesting that its stock price is 29% more volatile than the S&P 500.

Earnings and Valuation

This table compares Inhibrx Biosciences and BioNTech”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibrx Biosciences	$1.30 million	1,372.02	-$140.05 million	($8.88)	-13.65
BioNTech	$3.25 billion	8.08	-$1.29 billion	($7.83)	-13.25

Inhibrx Biosciences has higher earnings, but lower revenue than BioNTech. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Inhibrx Biosciences and BioNTech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Inhibrx Biosciences	N/A	-563.90%	-83.48%
BioNTech	-63.54%	-6.86%	-6.00%

Insider & Institutional Ownership

82.5% of Inhibrx Biosciences shares are held by institutional investors. Comparatively, 15.5% of BioNTech shares are held by institutional investors. 18.3% of Inhibrx Biosciences shares are held by insiders. Comparatively, 19.2% of BioNTech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

BioNTech beats Inhibrx Biosciences on 8 of the 14 factors compared between the two stocks.

About Inhibrx Biosciences

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.